LTZ Therapeutics, with operations in China, the U.S. and Germany, has closed a $17 million Series Pre-A round to develop immunotherapies to treat patients with cancer and other diseases. More news from Harbour BioMed, Everest Medicines, ASK Pharm, Abbvie, Antengene and BeiGene.
RNA specialist ExoRNA Bio has completed an angel round to raise dozens of millions of yuan to support its R&D and manufacturing of nucleic acid drugs for neurological disorders and anti-viral infectious diseases. More news from Everest Medicines, HanBio Therapeutics, Luzhu Biotech, Genmedicn, Chineo, Otovia Therapeutics, Kangrui Bio, Xbiome and Dizal Pharma.
Among the 22 deals Chinese drugmakers closed in September, 14 were worth $2.566 billion. Everest Medicines and Innovent Biologics dominated the dealmaking space with deals worth $1.06 billion and $529 million, respectively, representing 62% of the total value of all disclosed deals.